JP7408894B2 - チューブリン重合阻害活性及び免疫調節特性を有する化合物 - Google Patents

チューブリン重合阻害活性及び免疫調節特性を有する化合物 Download PDF

Info

Publication number
JP7408894B2
JP7408894B2 JP2020559423A JP2020559423A JP7408894B2 JP 7408894 B2 JP7408894 B2 JP 7408894B2 JP 2020559423 A JP2020559423 A JP 2020559423A JP 2020559423 A JP2020559423 A JP 2020559423A JP 7408894 B2 JP7408894 B2 JP 7408894B2
Authority
JP
Japan
Prior art keywords
group
alkyl group
hydrogen atom
independently
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020559423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522244A5 (https=
JPWO2019207257A5 (https=
JP2021522244A (ja
Inventor
モウアド アラミ，
オリヴィエ プロヴォット，
アブダラ ハムゼ，
イルヘム ケリフィ，
ティモシー ナレット，
セバスチャン アプチャー，
ロメイン ダリグランド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR) filed Critical Institut Gustave Roussy (IGR)
Publication of JP2021522244A publication Critical patent/JP2021522244A/ja
Publication of JP2021522244A5 publication Critical patent/JP2021522244A5/ja
Publication of JPWO2019207257A5 publication Critical patent/JPWO2019207257A5/ja
Application granted granted Critical
Publication of JP7408894B2 publication Critical patent/JP7408894B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2020559423A 2018-04-27 2019-04-26 チューブリン重合阻害活性及び免疫調節特性を有する化合物 Active JP7408894B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1853709A FR3080620B1 (fr) 2018-04-27 2018-04-27 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
FR1853709 2018-04-27
PCT/FR2019/050982 WO2019207257A1 (fr) 2018-04-27 2019-04-26 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Publications (4)

Publication Number Publication Date
JP2021522244A JP2021522244A (ja) 2021-08-30
JP2021522244A5 JP2021522244A5 (https=) 2022-05-02
JPWO2019207257A5 JPWO2019207257A5 (https=) 2022-05-02
JP7408894B2 true JP7408894B2 (ja) 2024-01-09

Family

ID=63036097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559423A Active JP7408894B2 (ja) 2018-04-27 2019-04-26 チューブリン重合阻害活性及び免疫調節特性を有する化合物

Country Status (9)

Country Link
US (2) US11634405B2 (https=)
EP (1) EP3784662B1 (https=)
JP (1) JP7408894B2 (https=)
AU (1) AU2019259112B2 (https=)
CA (1) CA3097622A1 (https=)
DK (1) DK3784662T3 (https=)
ES (1) ES2932370T3 (https=)
FR (1) FR3080620B1 (https=)
WO (1) WO2019207257A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825610B (zh) * 2020-06-24 2023-03-31 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途
CN115417860B (zh) * 2020-08-03 2023-10-20 中国药科大学 一种具有抗肿瘤活性的喹唑啉类衍生物及其合成方法和用途
CN113173915B (zh) * 2021-03-29 2022-12-09 中南大学湘雅医院 抗皮肤肿瘤化合物及其应用
CN113620874B (zh) * 2021-08-10 2024-02-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基-喹啉衍生物及其用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
JP2005511603A (ja) 2001-11-03 2005-04-28 アストラゼネカ アクチボラグ 抗腫瘍薬としてのキナゾリン誘導体
JP2008526776A (ja) 2005-01-03 2008-07-24 ミリアド ジェネティクス， インコーポレイテッド 脳癌の治療の方法
JP2008539216A (ja) 2005-04-29 2008-11-13 アストラゼネカ アクチボラグ Ｅｇｆおよび／またはｅｒｂｂ２受容体チロシンキナーゼの阻害剤としてのキナゾリン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
SK288365B6 (sk) * 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
AU2004289303A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
EA009994B1 (ru) * 2003-12-23 2008-06-30 Пфайзер Инк. Новые хинолиновые производные
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
FR2914640B1 (fr) 2007-04-04 2012-11-16 Centre Nat Rech Scient Iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de polymerisation de la tubuline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
JP2005511603A (ja) 2001-11-03 2005-04-28 アストラゼネカ アクチボラグ 抗腫瘍薬としてのキナゾリン誘導体
JP2008526776A (ja) 2005-01-03 2008-07-24 ミリアド ジェネティクス， インコーポレイテッド 脳癌の治療の方法
JP2008539216A (ja) 2005-04-29 2008-11-13 アストラゼネカ アクチボラグ Ｅｇｆおよび／またはｅｒｂｂ２受容体チロシンキナーゼの阻害剤としてのキナゾリン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mahal, Katharina; Resch, Marcus; Ficner, Ralf; Schobert, Rainer; Biersack,Mahal, Katharina et al.，Effects of the Tumor-Vasculature-Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels ，ChemMedChem，2014年，9(4),，847-854

Also Published As

Publication number Publication date
US11634405B2 (en) 2023-04-25
US20210230140A1 (en) 2021-07-29
CA3097622A1 (fr) 2019-10-31
AU2019259112A1 (en) 2020-11-26
US12371417B2 (en) 2025-07-29
WO2019207257A8 (fr) 2019-11-21
EP3784662A1 (fr) 2021-03-03
EP3784662B1 (fr) 2022-11-09
WO2019207257A1 (fr) 2019-10-31
ES2932370T3 (es) 2023-01-18
DK3784662T3 (da) 2022-12-19
FR3080620B1 (fr) 2021-11-12
US20230203005A1 (en) 2023-06-29
AU2019259112B2 (en) 2024-02-08
JP2021522244A (ja) 2021-08-30
FR3080620A1 (fr) 2019-11-01

Similar Documents

Publication Publication Date Title
JP7408894B2 (ja) チューブリン重合阻害活性及び免疫調節特性を有する化合物
TWI704142B (zh) 抗癌劑1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)環丙胺的製備方法、及其藥物的結晶形及其鹽類
TWI287004B (en) A pyridone derivative having an affinity effect for cannabinoid 2 type receptor
CA2913840C (en) Compounds with anti-cancer activity
JP2025023997A (ja) Ｆａｋ阻害剤およびその併用薬物
JP4836396B2 (ja) ナフタレン誘導体
WO2016184434A1 (zh) 一种吡啶并氮杂环化合物及其制备方法和用途
CN106995437A (zh) 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
WO2021143753A1 (zh) 基于吲哚母核的atx抑制剂及其制备方法和应用
CN105585565B (zh) 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
TW201641492A (zh) 經取代1,2,3-三唑、其用途、以及包含其之醫藥組成物
WO2015021894A1 (zh) 新型羟肟酸衍生物及其医疗应用
JP7664861B2 (ja) 眼障害の治療のための化合物
CN104530038A (zh) 酰胺咪唑类衍生物及其用途
CN1830964B (zh) 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途
CN107141287B (zh) 2-亚胺-5-酮基-2,5-二氢-1-h-二吡啶并嘧啶类化合物
WO2019029295A1 (zh) 基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用
EP4065572A1 (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
CN116751161A (zh) 喹啉类化合物及其制备方法、药物组合物及医药用途
US20170057910A1 (en) Antitumor naphthalenyl benzamide derivatives
CN108187055B (zh) 一种具有协同增效作用的抗癌组合物
CN107056754B (zh) 内嵌脲类结构的wnt通路抑制剂
CN115340526B (zh) 邻二甲酰亚胺类化合物及其药物组合物、制备方法和用途
CN121591767A (zh) 一种含有碳硼烷的化合物及其用途
CN103936719A (zh) 苯并咪唑类衍生物制备方法及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231124

R150 Certificate of patent or registration of utility model

Ref document number: 7408894

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150